SCHEMBL4364867

SCHEMBL4364867

CC(=CC=C1SC(N2CCOCC2)=NC1=O)c1ccc(C(C)(C)C)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.53
ALDH1A1 P00352 8/20 0.53
NPSR1 Q6W5P4 2/20 0.53
MAPK1 P28482 1/20 0.53
SMN1; SMN2 Q16637 5/20 0.51
RAB9A P51151 4/20 0.51
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
NPC1 O15118 2/20 0.51
CYP1A2 P05177 2/20 0.51
CYP2C19 P33261 2/20 0.51
HCRTR1 O43613 1/20 0.51
GAA P10253 2/20 0.47
HPGD P15428 1/20 0.47
LMNA P02545 4/20 0.44
PSMD14 O00487 1/20 0.44
RECQL P46063 1/20 0.43
POLB P06746 2/20 0.42
GPR55 Q9Y2T6 1/20 0.42
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4364864 1.00 MAPT (0.53) MAPTALDH1A1NPSR1MAPK1SMN1; SMN2
SCHEMBL4358508 0.91 MAPT (0.50) MAPTALDH1A1NPSR1MAPK1SMN1; SMN2
SCHEMBL4358503 0.91 MAPT (0.50) MAPTALDH1A1NPSR1MAPK1SMN1; SMN2
SCHEMBL4346313 0.88 SMN1; SMN2 (0.64) MAPTALDH1A1NPSR1SMN1; SMN2RAB9A
SCHEMBL4346315 0.88 SMN1; SMN2 (0.64) MAPTALDH1A1NPSR1SMN1; SMN2RAB9A
SCHEMBL4350554 0.85 RAB9A (0.52) MAPTALDH1A1NPSR1SMN1; SMN2RAB9A
SCHEMBL4350552 0.85 RAB9A (0.52) MAPTALDH1A1NPSR1SMN1; SMN2RAB9A
SCHEMBL4357379 0.81 MAPT (0.50) MAPTALDH1A1NPSR1SMN1; SMN2RAB9A
SCHEMBL4357381 0.81 MAPT (0.50) MAPTALDH1A1NPSR1SMN1; SMN2RAB9A
SCHEMBL4350499 0.81 MAPT (0.74) MAPTALDH1A1NPSR1MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP claimed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 MAPT 1470/4885ALDH1A1 284/4885NPSR1 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.